Hepatology

The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.

The study's findings show an association between NAFLD prevalence, physical activity, and television viewing, with higher levels of physical activity paired with lower levels of television viewing leading to a statistically significantly reduced risk of NAFLD.

Performance metrics of NIS4, the ELF test, and FibroMeter VCTE met prespecified criteria for qualification for regulatory approval in stage 1 of the NIMBLE project's circulating biomarker workstream.

Investigators noted the prevalence of metabolic syndrome was highest among participants with obesity, linking increased BMI to a greater risk of metabolic syndrome and NAFLD severity.

The University of Miami study previews the upcoming phase 3 trial and what the investigative seladelpar may provide patients with primary biliary cholangitis.

The phase 3 seladelpar investigator discusses the current landscape of care available for patients with PBC.

This endocrine case report from Brady Pregerson, MD, features a patients in his mid-70s with a history of hypothyroidism presenting with weeks of nausea, vomiting, and diarrhea without blood but with a 30-pound weight loss. Can you determine the most likely diagnosis?

A number of innovative, virus-targeting agents are under investigation to treat HCV—or even prevent it.

Results from the retrospective cohort study indicated viral eradication with DAAs after liver transplantation improved liver function and patient survival after a long-term follow-up, even in cirrhotic patients.

Investigators highlighted an association between treatment retention over time and the out-of-pocket cost for patients with hepatic encephalopathy taking rifaximin.

Hypertension prevalence was significantly higher among adults with obesity and severe NAFLD, providing important information related to the association between hypertension and NAFLD severity.

A systematic review shows the muscle relaxant therapy is the lone intervention to benefit outcomes for the liver diseases among patients with alcohol use disorder, per randomized trials.

Investigators identified a strong magnitude of association between MAFLD and risk of CKD based on the results of a comprehensive meta-analysis.

A new study revealed differences in the diagnostic performance of the FIB-4 and NFS, indicating that conventional NFS cutoff values may be unsuitable for screening lean NAFLD patients.

Investigators find that while general hospitalizations decreased in 2020, hospitalizations due to alcohol-associated hepatitis increased by 16%.

New 12-week data shows an investigative oral drug provided significant benefit in key outcomes associated with NASH disease relief.

An analysis of postmenopausal women shows a nearly two-fold increase in liver cancer incidence among those who consume at least 1 soft drink or fruit drink daily.

Approximately 1 in 5 newly diagnosed patients are initiating direct acting antivirals within 6 months, according to Medicaid data review.

Experts in hepatology review the unmet needs in primary biliary cholangitis, commenting on liver transplant, ethnic disparities, management of pruritis, as well as other symptoms.

Sonal Kumar, MD, MPH, and David Victor III, MD, provide an overview of the emerging treatments in the primary biliary cholangitis landscape, highlighting PPAR agonists and combination OCA and bezafibrate.

A multinational study shows people who achieve sustained virologic response still face a 3-fold greater risk or more of mortality due to liver disease or drug-related issues.

Global estimate prevalence data suggest the virus affects more than 3% of the population, with available treatment and vaccination strategies used too infrequently.

New cross-sectional data show the sex gap in alcohol-related mortality has been narrowing since 1999, as women have become more susceptible to alcohol use and related diseases.

Hepatology experts discuss the use of triple therapy in the management of PBC as the wave of the future.

Experts in hepatology comment on how long they keep a patient with PBC on first-line treatment before deciding to switch to another therapy.